Radius Health Inc
Radius (RDUS) is a biopharmaceutical company engaged in innovative development, with a special focus on oncology, osteoporosis and endocrine diseases. The company was founded in 2003. With offices in Waltham, Cambridge, Parsippany, Massachusetts, New Jersey and Wayne, Radius is now engaged in developing a selective estrogen receptor degrader called RAD1901. Also, the company works on RAD140, an investigational selective androgen receptor modulator drug. Radius Health is traded on the NASDAQ stock exchange and the company is headquartered in Waltham, USA.